Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis by Meyer, Nicholas et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.4088/JCP.14m09326
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Meyer, N., Gee, S., Whiskey, E., Taylor, D. M., Mijovic, A., Gaughran, F., ... MacCabe, J. H. (2015). Optimizing
outcomes in clozapine rechallenge following neutropenia: a cohort analysis. Journal of Clinical Psychiatry,
76(11), e1410-6. https://doi.org/10.4088/JCP.14m09326
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
  
1 
Optimising outcomes in clozapine rechallenge following neutropenia: a cohort 
analysis. 
 
Nicholas Meyer MRCPsych 1 
Siobhan Gee MPharm 2,3 
Eromona Whiskey MPharm 3 
David Taylor PhD 3 
Aleksandar Mijovic FRCPath 4 
Fiona Gaughran FRCP 1,2 
Sukhi Shergill FRCPsych1,2 
James H. MacCabe MRCPsych1,2 
 
1  Department of Psychosis Studies, Institute of Psychiatry, Psychology and 
Neuroscience, King’s College London 
2  National Psychosis Unit, Bethlem Royal Hospital, South London and Maudsley 
NHS Foundation Trust, London  
3  Department of Pharmacy, South London and Maudsley NHS Foundation Trust, 
London  
4  Department of Haematological Medicine, King’s College Hospital, London 
 
Role of the sponsor: The sponsors had no role in the design, conduct, analysis, or 
interpretation of this work.  This study presents independent research supported by 
the National Institute for Health Research (NIHR)/Wellcome Trust King’s Clinical 
Research Facility and NIHR Biomedical Research Centre at South London and 
Maudsley NHS Foundation Trust and King’s College London. The views expressed 
are those of the authors and not necessarily those of the NHS, the NIHR or the 
Department of Health. 
 
Previous presentation: This work has not been presented previously.  
 
Disclaimer statements: Fiona Gaughran has received fees for lectures/ advisory 
work or research support from BMS, Sunovion, Roche, Lundbeck, Abbvie and has 
family professional links to GSK and Lilly.  David Taylor has received research 
funding from Janssen, Lundbeck and Servier; consultancy fees from Sunovion, and 
lecturing honoraria from Janssen, Otsuka and Servier.  
 
  
2 
Correspondence to: Nicholas Meyer BA BMBCh MRCPsych, Department of 
Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, 16 De 
Crespigny Park, London SE5 8AF, UK; nicholas.meyer@kcl.ac.uk; tel: 020 7848 
0355; fax: 020 7848 0976 
 
Abbreviations: ANC: absolute neutrophil count; WCC: white cell (leucocyte) count; 
BEN: benign ethnic neutropenia; G-CSF: granulocyte-colony stimulating factor; NPU: 
National Psychosis Unit 
 
Keywords: clozapine, rechallenge, neutropenia, agranulocytosis, benign ethnic 
neutropenia, G-CSF 
 
  
3 
 
Abstract 
 
Objective: 
Certain patients with treatment-refractory schizophrenia may be rechallenged with 
clozapine following previous neutropenia.  Evidence guiding patient selection and the 
effectiveness of lithium and granulocyte-colony stimulating factor (G-CSF) in 
rechallenge is limited, and factors associated with successful outcomes are unclear.   
 
Method: 
Outcomes were studied in patients rechallenged with clozapine at a tertiary referral 
centre between January 2007 – December 2013, following one or more previous 
trials terminated due to neutropenia, defined as an absolute neutrophil count (ANC) 
<1.5 x 109/L.  Demographic characteristics, details of each clozapine trial including 
ANC and co-prescribed medication were extracted and factors associated with 
rechallenge outcomes examined.  
 
Results: 
Nineteen patients underwent clozapine rechallenge following previous neutropenia; 
four (21%) experienced further neutropenia, two of which were agranulocytosis.  
Compared to successfully rechallenged patients, unsuccessful rechallenges were 
significantly older (t=2.10, p=0.05), onset of neutropenia was sooner (W=10.0, 
p=0.03), and valproate co-prescription was more common.  In addition to five 
patients with benign ethnic neutropenia (BEN), 8/10 patients not of an ethnicity 
associated with BEN also had idiopathic low neutrophil counts at baseline; lithium 
and G-CSF co-prescription facilitated successful rechallenge in these patients. 
 
Conclusion:  
In this selected population, the initial neutropenia was unlikely to be related to 
clozapine in a substantial proportion of cases.  This group was successfully 
rechallenged following careful consideration of the risks and benefits, and lithium and 
G-CSF contributed to allowing continued clozapine therapy.  In addition to Black 
patients, other ethnic groups can have persistently low ANC unrelated to clozapine.  
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Introduction  
 
Clozapine is an antipsychotic with unique efficacy in treatment-refractory 
schizophrenia1.  In the UK, clozapine is recommended in patients who have failed to 
respond to trials of at least two different antipsychotics at adequate doses2.  
However, first-line use is limited by its propensity to cause neutropenia3 and 
potentially fatal agranulocytosis4 in 3% and 0.8% of patients respectively, and regular 
haematological monitoring is mandatory for all patients receiving clozapine.  Patients 
developing haematological dyscrasia are excluded from further licensed treatment.    
 
Nonetheless, in certain individuals where illness is severe and a good response to 
clozapine was observed, off-label rechallenge of clozapine may be attempted after 
careful consideration of the risks and benefits5.  In particular, cases where the 
original dyscrasia was likely to have been due to factors other than clozapine may 
benefit from rechallenge.  Co-administration of other drugs which interact with 
clozapine, or in themselves cause haematological toxicity, may account for, or 
contribute to, some cases of neutropenia6.  Benign ethnic neutropenia (BEN) affects 
25-50% of people of African ancestry, as well those of Arabic-Middle Eastern 
descent7; 8, and has been recognised as a factor contributing to clozapine 
discontinuation in these populations9.  The use of modified monitoring criteria for 
BEN populations10, co-administration of lithium11 and G-CSF12 have been used to 
augment leucocyte counts and avoid treatment interruption or discontinuation.   
 
Due to the risk of agranulocytosis, patients and clinicians are understandably 
hesitant to undertake clozapine rechallenge, and it remains uncommon. The 
evidence base guiding practice is correspondingly sparse.  The largest study 
consisted of 53 patients rechallenged in the UK over a five year period13, of whom 20 
(38%) experienced a further dyscrasia, nine of which were agranulocytoses.  No 
clear risk factors for repeat dyscrasia were identified, however the second dyscrasia 
was more severe, more prolonged and occurred sooner.  Kanaan and Kerwin14 
studied 25 rechallenges with co-prescribed lithium, and reported that only one (4%) 
had a second episode of neutropenia, suggesting that lithium improved the 
probability of success.  A systematic review15 including the two studies mentioned 
above reported 112 cases of rechallenge following neutropenia of which 34 (30%) 
failed, and 15 rechallenges following agranulocytosis of which 12 (80%) experienced 
further dyscrasia.   
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Further evidence guiding the selection of patients for rechallenge based on their 
previous haematological profile is therefore needed, as is evidence regarding the 
utility of treatments aimed at augmenting leucocyte counts.  Observational studies of 
clozapine rechallenge offer important insights in this regard. 
 
The National Psychosis Unit (NPU) is a tertiary centre admitting patients from across 
the UK for the management of treatment-refractory schizophrenia.  A significant 
proportion have previously discontinued clozapine due to haematological adverse 
events, and therefore form a unique population in which to study clozapine 
rechallenge.  We report the outcomes of 19 adult inpatients selected for clozapine 
rechallenge following previous leucopenia or neutropenia, and examine whether 
particular clinical characteristics are associated with outcome.  We focus on the 
efficacy, safety and tolerability of adjunctive measures including lithium and G-CSF.   
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Methods   
 
All admissions to the NPU between 1 January 2007 and 31 December 2013 were 
screened for inclusion.  Inclusion criteria comprised at least one previous episode of 
clozapine therapy discontinued due to concurrent leucopenia and/or neutropenia, 
and subsequent clozapine rechallenge on the unit.  Leucopenia was defined as a 
white cell count (WCC) <3.0 x 109/L, neutropenia as an absolute neutrophil count 
(ANC) <1.5 x 109/L, and agranulocytosis as a ANC <0.5 x 109/L. 
 
Demographic information, psychiatric diagnosis, characteristics of each clozapine 
trial (duration, dose, neutrophil nadir, duration of neutropenia), alternative 
explanations for neutropenia (co-morbid medical conditions, benign ethnic 
neutropenia, co-prescription of drugs reported to have a definite or probable causal 
association with neutropenia and agranulocytosis6; 16), and the use of adjunctive 
treatments (lithium and G-CSF), were extracted from the patient record.  Ethnic 
group was classified according to guidelines from the Office for National Statistics, 
UK17: White, Mixed, Asian (from any part of the Asian continent, including Chinese), 
Black, and Other ethnic group (including Arab).   
 
Full blood counts during treatment and, where possible, complete historical blood 
counts were obtained. Successful rechallenge was defined as continued clozapine 
therapy until discharge from the unit, and unsuccessful rechallenge being defined as 
recurrence of leucopenia, neutropenia or agranulocytosis prior to discharge.  Blood 
tests during the follow up period were performed in accordance with guidelines from 
the clozapine monitoring service18 (weekly for the first 18 weeks, and at four-week 
intervals thereafter), with the exception of those with a BEN-pattern receiving G-CSF, 
who had an increased frequency of monitoring (twice-weekly or on alternate days) 
during the initial phase of treatment, on the advice of the haematologist.   
 
The t-test for independent and matched samples was used to compare differences in 
age and between and within group differences in ANC, and the Mann-Whitney and 
Wilcoxon signed rank test to compare treatment duration between and within groups 
respectively.  Categorical variables were compared using the chi-square test.  All 
reported p-values are two-sided.  Statistical analysis was undertaken using SPSS 
2219. 
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Approval was obtained from the Drugs and Therapeutics Committee, South London 
and Maudsley NHS Foundation Trust, and the study complies with the standards laid 
down in the Declaration of Helsinki. 
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Results 
 
146 patients were admitted over the study period, of whom 51 were rechallenged 
with clozapine. Nineteen of these patients had experienced previous clozapine-
associated neutropenia that resulted in treatment discontinuation; all had primary 
ICD-10 diagnoses of schizophrenia. Rechallenge was successful in 15 patients 
(79%), and unsuccessful in four (21%) (table 1).  Fourteen had undergone one 
previous trial of clozapine and five had undergone two previous trials, four of which 
were successfully rechallenged.  None of the patients selected for rechallenge had 
previous agranulocytosis, on the basis of evidence suggesting rechallenge in this 
group is highly unlikely to succeed20.   
 
 All patients  
N = 19 
 
Successful 
rechallenge  
N = 15  
Failed rechallenge  
N = 4 
 
Patient characteristics 
Sex, n (%) 
   Male 
   Female 
 
15 (79) 
4 (21) 
 
12 (80) 
3 (20) 
 
3 (75) 
1 (25) 
Age at time of 
rechallenge: mean (SD) 
 
30.7 (7.4) 
 
29.0 (5.7) 
 
37.0 (10.4) 
Ethnicity, n (%) 
   White 
   Black 
   Asian 
   Mixed  
   Other 
 
12 (63) 
3 (16) 
2 (11)  
1  (5) 
1  (5) 
 
9 (60) 
3 (20) 
2 (13) 
1   (7) 
0 
 
3 (75) 
0 
0 
0 
1 (25)  
First exposure characteristics 
ANC nadir on first 
exposure/ x 109/L, 
mean (range) 
1.26 (0.70 – 1.90) 1.33 (0.80 – 1.90) 1.08 (0.70 – 1.50) 
Treatment duration/ 
weeks: median (range) 
28.6 (0.9 – 434.7) 28.6 (0.9 – 434.7) 34.6 (9.6 – 100.1) 
Duration of break from 
clozapine treatment*/ 
weeks, median (range) 
  99.6 (4.0 – 660.0) 94.0 (4.0 – 544.7) 146.1 (56.9 – 660.0) 
Rechallenge characteristics  
ANC nadir on 
rechallenge/ x 109/L, 
mean (range) 
n/a n/a 0.56 (0.16 – 0.86) 
Duration of follow up**/ 
time to neutropenia/ 
weeks, median (range) 
34 (3.0 – 88.4) 40.6 (8.0 – 88.4) 3.9 (3.0 – 5.7) 
Duration of follow up to 
at least: n (%) 
   3 months:  
   6 months:  
   9 months:   
   12 months: 
  
 
14 (93) 
13 (87) 
8 (53) 
5 (33) 
 
 
n/a 
 
Treated with valproate 
on rechallenge n (%) 
 3  (20) 3  (75) 
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Table 1: Patient characteristics, times to neutropenia and neutrophil count nadir on 
first and rechallenge exposures to clozapine.  
*In patients with more than one previous trial, the duration between the end of the 
first and beginning of the most recent trials are reported.   
** Follow up is defined as time from re-initiation of clozapine until discharge from the 
ward, or to recurrence of neutropenia. 
 
Unsuccessful rechallenge 
 
All four unsuccessful rechallenges had pre-treatment ANC consistently above 2 x 
109/L, thus not meeting criteria for benign neutropenia, and all developed 
neutropenia below 1.0 x109/L on rechallenge, and one developed agranulocytosis 
(table 2).  Clozapine dose range at neutropenia onset was 175 – 350 mg/day.  Mean 
age was significantly higher than those successfully rechallenged (t=2.10, p=0.05).  
Comparing unsuccessful and successful rechallenges, the difference in ANC nadir 
on first exposure was non-significant (t=1.4, p=0.18), and duration of initial exposure 
to clozapine was shorter, though this difference was not statistically significant 
(U=25.0, p=0.67).  Onset of neutropenia on rechallenge was sooner (34.6 vs. 3.9 
weeks, W=10.0, p=0.03) and more severe than following initial exposure (neutrophil 
nadir of 0.56 x109/L vs. 1.08 x109/L) though this was non- significant (t=1.7, p=0.19). 
The median time to recovery of neutrophils following rechallenge was 8 days (range 
4 – 19).  Three of four (75%) patients failing rechallenge were prescribed valproate 
on rechallenge, compared with 3/15 (20%) who were successfully rechallenged (chi-
square= 4.42; p=0.07).  All other co-prescribed drugs associated with neutropenia 
are outlined in table 2.   
 
Patient Age Ethnic 
group 
Duration 
of first 
exposure/
weeks 
Duration of 
rechallenge 
/weeks 
ANC 
nadir on 
first 
exposure  
cells x 
109/L 
ANC nadir 
on 
rechalleng
e cells x 
109/L 
Duration 
neutro-
penia on 
rechalleng
e/ days 
Concurrent 
medication on 
rechallenge  
1  37 White 43 3 0.7 0.85 4 Lithium 
Valproate b  
2a  51 White 100 
10 
3 1.5 
0.9 
0.16 9 Lithium 
Valproate b 
Amisulpride 
Sprinolactone b 
Ramipril b 
3  26 White 9 4 0.8 0.36 7 Lithium 
G-CSF  
4  34 Other 26 5 1.3 0.86 19 Lithium 
Valproate b 
G-CSF  
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Table 2: Characteristics of the four patients failing rechallenge. 
a This patient had two previous trials, both discontinued due to neutropenia.  
b Known association with neutropenia 
 
Patient 1 had spontaneous recovery of ANC on discontinuation of clozapine.  Patient 
2 developed agranulocytosis and required hospital admission for treatment of febrile 
neutropenia, and ANC recovered.  Patient 3 received G-CSF on developing 
neutropenia and continued to receive clozapine, in line with a plan agreed with 
haematologists.  Despite this, agranulocytosis developed, at which point clozapine 
was discontinued and the patient transferred to a general hospital.  Further G-CSF 
was administered and the patient made a good recovery.  Patients 1-3 demonstrated 
a characteristic profile of a spike in ANC within a fortnight prior to neutropenia onset, 
and a rebound leucocytosis following resolution (figure 1a).  
 
Patient 4 experienced protracted neutropenia and leucopenia on week five of 
treatment, after which clozapine was discontinued and G-CSF administered 19 days 
after the onset of neutropenia.  A robust granulopoeitic response was observed 
(peak ANC of 15.2 and WCC of 17.7).  Due to continued severe psychotic 
symptoms, a further rechallenge with clozapine was reattempted four months later 
following haematological consultation, with concurrent G-CSF cover (not shown in 
table 2).  The response to G-CSF was however attenuated (ANC range 2.03 – 5.38; 
WCC 2.86 – 6.74) and ANC continued a downward trend.  Rechallenge was 
abandoned after 25 days, and ANC normalised following discontinuation of 
clozapine.   
 
Successful rechallenge 
 
Following haematological consultation, 5/15 (33%) of the successfully rechallenged 
patients were diagnosed with BEN on the basis of a pre-clozapine ANC persistently 
below normative thresholds, their ethnicity (Black (n= 3), Asian (n=1) and Mixed 
(n=1)) and an absence of alternative explanations for persistent neutropenia.  For 
these patients, the use of modified monitoring criteria10 was agreed with the 
clozapine monitoring service prior to clozapine initiation, with an initially increased 
frequency of blood monitoring (twice a week for the first 12 weeks).  In all cases, 
other agents known to cause neutropenia were discontinued prior to initiation, and 
lithium augmentation was trialled at a therapeutic dosage (>0.4 mmol/L 12 hours 
post-dose) and continued in all but one patient. 
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Despite the use of lithium and BEN monitoring criteria, the baseline pre-clozapine 
ANC in two patients frequently fell below 1.0 x 109/L, and was too low to permit 
initiation and maintenance of clozapine.  G-CSF was therefore administered on a 
twice-weekly basis prior to and throughout clozapine treatment to allow continued 
dispensing of clozapine by the monitoring service (figure 1b).  Granocyte® 105 mcg 
twice weekly (lenograstim, Chugai, Tokyo, Japan) and Neupogen® 150 mcg twice 
weekly (filgrastim, Amgen, Vienna, Austria) were administered subcutaneously in 
either case; further details of the G-CSF administration protocol are described in a 
previously published case report 12.  No significant side-effects of G-CSF were 
reported. 
 
Though their ethnicity precluded a formal diagnosis of BEN, 8/15 (53%) of the 
successfully rechallenged patients demonstrated a similar pattern of constitutionally 
low neutrophils that preceded clozapine treatment, with fluctuating pre-clozapine 
neutrophil counts whose lower limit frequently neared, or breached, the lower 
threshold of 2.0 x 109/L.  Seven were White, and one was Asian.  Alternative reasons 
for neutropenia were excluded, and where possible other drugs associated with 
neutropenia were discontinued.  Six patients received lithium for ANC augmentation, 
and four had a plan agreed with a haematologist for G-CSF administration in the 
event of a neutropenia in the low-amber (near 1.5 x 109/L) or red (<1.5 x 109/L) 
range.  Two patients received a single dose of G-CSF following an amber or red 
neutropenia, and were able to continue treatment (figure 1c).   
 
The remaining 2/15 (13%) successfully rechallenged patients were White, and did 
not have an ANC at baseline consistent with chronic neutropenia.  Both were 
prescribed lithium.  One patient had a sustained drop in baseline ANC four weeks 
after clozapine initiation, as shown in figure 1d. 
 
Additional co-prescribed medications in the 10 patients without BEN were lamotrigine 
(n = 2), valproate (n = 3), amisulpride (n = 2) and aripiprazole (n = 1).  Of these, 
lamotrigine and valproate are associated with neutropenia. 
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Figure 1: illustrative haematological profiles of failed (a) and successful (b – d) 
rechallenges.  0 on the ordinal axis indicates admission; note different scale in 
figure (a). 1a: agranulocytosis with spontaneous recovery in patient 2, note 
spike in ANC prior to neutropenia, and rebound on recovery. 1b: BEN patient, 
administered G-CSF on a twice weekly basis.  1c: White patient with low 
baseline ANC.  Spike represents administration of G-CSF following red result. 
1d: White patient who developed a drop in mean ANC four weeks after 
commencing clozapine but was able to continue treatment with lithium and a 
single administration of G-CSF. 
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Discussion  
 
In this the third largest series of clozapine rechallenge in adults, we have shown that 
in a selected group of inpatients with severe treatment refractory illness, 15/19 (79%) 
of patients were successfully re-established on clozapine following previous 
treatment-emergent leucopenia or neutropenia.  This is higher than that of Dunk and 
colleagues13 reporting successful rechallenge in 62% (32/52), and comparable to the 
24/25 (96%) success rate reported previously by our unit14.  We believe this 
demonstrates the importance of carefully selecting patients who have a relatively 
reduced risk of a neutropenia based on their previous history, and optimising 
rechallenge with adjunctive treatments. 
 
The mechanisms of clozapine-induced neutropenia and agranulocytosis remain 
uncertain21.  There may exist a unitary process, where neutropenia progresses 
inevitably to agranulocytosis if clozapine is not terminated21.  An alternative 
hypothesis posits two distinct mechanisms, one leading to agranulocytosis, and 
another to persistent neutropenia but not agranulocytosis6.   
 
Given that the haematological outcomes on rechallenge are likely to reflect the cause 
underlying discontinuation in earlier trials, we hypothesise the following categories 
based on the rechallenge outcomes observed in our cohort: 1) clozapine-induced 
agranulocytosis, or neutropenia that would otherwise have progressed to 
agranulocytosis, with a characteristic pattern and time-course; 2) persistent 
neutropenia that does not progress to agranulocytosis that may be related to 
clozapine but also the co-prescription of other agents, and 3) idiopathic, persistent 
neutropenia (not restricted to those with ethnicity associated with BEN) unrelated to 
clozapine or other agents.  We suggest that groups 2 and 3 can be considered for 
rechallenge with specialist input.  
 
Factors associated with unsuccessful rechallenge 
 
Consistent with established findings that age is a risk factor for clozapine-induced 
dyscrasia3; 4, patients who developed neutropenia on rechallenge were significantly 
older. Similar to the finding by Dunk et al13, patients who failed rechallenge had a 
more severe and rapid onset of subsequent neutropenia, suggesting an immune-
mediated mechanism.  
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Three out of four patients developing neutropenia on rechallenge showed a spike in 
ANC in the fortnight preceding dyscrasia, a phenomenon which was found to be a 
sensitive but non-specific predictor of agranulocytosis22.  A possible mechanism is 
the production of endogenous granulopoeitic factors that initially compensates for the 
incipient fall in granulocytes.  The response to G-CSF was attenuated in two patients 
who failed rechallenge, in comparison to BEN patients whose granulopoietic 
response did not diminish despite successive administrations or G-CSF.  This 
suggests that attenuation in response to G-CSF is an indicator of injury to the 
granulocyte precursors in the bone marrow, and that clozapine should be 
discontinued immediately.   
 
Factors associated with successful rechallenge 
 
Successful rechallenge was associated with a shorter median duration of first 
exposure to clozapine: one explanation might be that these patients failed their first 
trial early in treatment due to constitutionally low neutrophils, and not clozapine 
toxicity.  Over half of the successfully rechallenged patients were White, and 
therefore ineligible for BEN criteria, but nonetheless had consistently low pre-
clozapine ANC.   This is consistent with previous studies9 that suggest ANCs at the 
lower end of the population distribution in otherwise asymptomatic individuals is a 
common reason for clozapine discontinuation, and does not necessarily indicate 
clozapine toxicity.  Therefore, correctly identifying this haematological pattern is 
critical in selecting patients who are likely to be successfully rechallenged.  Four out 
of five patients who had undergone more than one previous trial were successfully 
rechallenged, suggesting that multiple trials are not necessarily associated with 
unsuccessful rechallenge. 
 
Treatment with lithium and G-CSF  
 
All of the patients who developed neutropenia on rechallenge were prescribed 
lithium, suggesting that, in these patients, it does not protect against clozapine-
induced neutropenia.  Similarly, responses to G-CSF were attenuated in patients 
who failed rechallenge, also arguing that G-CSF is not protective against clozapine-
induced neutropenia in these patients. 
 
  
16 
Of the successful rechallenges, 4/5 of the BEN patients and 8/10 of the remaining 
patients received lithium, suggesting that lithium has utility in increasing ANC and 
avoiding treatment discontinuation.  Two BEN patients received regular G-CSF, and 
three White patients received single doses of G-CSF, indicating that G-CSF can also 
play a role in facilitating uninterrupted treatment with clozapine.   
 
However, lithium may compromise neutrophil function23; 24, and no studies have 
investigated the rate of infection in lithium treatment.  Furthermore, the use of G-CSF 
in allowing continued clozapine therapy is contentious.  In addition to commonly 
reported acute side-effects such as bone pain25 in patients receiving G-CSF following 
chemotherapy, the safety of long-term treatment with G-CSF is unknown. 
Osteopenia26 and splenic enlargement27 have been described, and we recommend 
monitoring of bone density and spleen size in long-term G-CSF use.  
 
Implications for clinical practice and future research 
 
Our findings suggest that current concepts of BEN are too narrow, and leads to 
unnecessary discontinuation of clozapine in those with a picture of idiopathic 
neutropenia.  ANCs of 0.5 – 1.5 x 109/L, defined haematologically as ‘mild to 
moderate neutropenia’ are not associated with a significantly increased risk of 
infection28.  Consideration should therefore be given the use of lowered thresholds to 
patients of other ethnicities, following haematological evaluation.  The use of 
definitions such as chronic idiopathic neutropenia 29 may aid this process.  Future 
approaches to differentiating clozapine-induced neutropenia from incidental 
neutropenia unrelated to clozapine may include consideration of dynamic trends in 
ANC relative to an individual’s baseline pre-clozapine ANC, rather than the absolute 
counts relative to an arbitrary threshold.  
 
We could not clearly identify a subset of patients who develop a milder form of 
clozapine-induced neutropenia, although the trend in one case (figure 1d) did 
support the existence of such a pattern.  Further work is necessary to identify 
whether clozapine can cause a milder neutropenia, or induces fluctuations in ANC.   
 
Where possible, other drugs associated with neutropenia were stopped prior to 
rechallenge.  However, 3/4 (75%) patients failing rechallenge were co-prescribed 
valproate, compared to 3/15 (20%) who were successfully rechallenged.  Clozapine 
in combination with valproate has been associated with a greater risk of neutropenia 
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than with either drug alone30, and a case of treatment-emergent neutropenia with 
clozapine and valproate that resolved on withdrawal of valproate has been 
reported31.  When considering rechallenge, the potential role of valproate in 
contributing to neutropenia should be borne in mind. 
 
The requirement for haematological monitoring has led to a greater awareness of 
clozapine-induced neutropenia.  However, other serious medical complications such 
as cardiomyopathy, ileus or diabetic ketoacidosis are reported to have caused more 
deaths than agranulocytosis32, and deserve equal emphasis.  Future research should 
examine the relative risks of all complications, not only haematological, as well as the 
circumstances in which rechallenge may be appropriate. Finally, the benefits of 
clozapine in reducing suicide33 and overall mortality34; 35 must be balanced against 
these risks. 
 
Limitations 
 
Clozapine rechallenge is a rare occurrence, and the small number of cases reported 
here reflects this.  The statistical analyses and conclusions in relation to the 
unsuccessful rechallenge group should therefore be interpreted with caution.  A 
further limitation of this study arises from its retrospective observational design.  
Follow-up ended when patients were discharged from the service, with a median 
duration of follow-up in successfully rechallenged patients of 41 weeks.  It is 
therefore possible that some of these individuals developed neutropenia after 
discharge.  However, other rechallenge studies with longer follow-up found a median 
time to dyscrasia of 5.5 weeks13, suggesting that most dyscrasia occurs soon after 
restarting clozapine.   
 
The severity of psychosis in our patient group did not permit a drug-free period prior 
to clozapine initiation.  Therefore, other antipsychotics associated with neutropenia 
such as olanzapine and risperidone6 may have contributed to the persistent pre-
clozapine neutropenia observed in some patients.  It remains extremely difficult to 
demonstrate that a given drug contributes to dyscrasia when prescribed in 
conjunction with clozapine, and case reports have been conflicting36.   
 
The highly selected patient group and setting may limit the generalizability of our 
findings; patients with BEN or other benign neutropenia may be over-represented in 
our sample, and not all centres will have experience in using G-CSF.  Definitions of 
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ethnic groups are imprecise37, and the categories used in this study overlook the 
significant diversity that exist within populations.  
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Clinical points 
 
• Neutropenia is a frequent reason for discontinuing clozapine, and there is 
often uncertainty over attempting rechallenge. 
 
• This study suggests that with careful selection and support from a 
haematologist, some patients can be successfully rechallenged following 
neutropenia.  
 
• Look carefully at circumstances of initial neutropenia.  Consider whether 
benign ethnic neutropenia (BEN), co-prescribed medications and medical 
conditions could have been responsible.   
 
• In cases of BEN, lithium and G-CSF may aid rechallenge.  White patients can 
also present with a picture of persistent neutropenia identical to BEN. 
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